These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 28182587)

  • 1. Evolution of Quality Assurance for Clinical Immunohistochemistry in the Era of Precision Medicine - Part 2: Immunohistochemistry Test Performance Characteristics.
    Torlakovic EE; Cheung CC; D'Arrigo C; Dietel M; Francis GD; Gilks CB; Hall JA; Hornick JL; Ibrahim M; Marchetti A; Miller K; van Krieken JH; Nielsen S; Swanson PE; Vyberg M; Zhou X; Taylor CR;
    Appl Immunohistochem Mol Morphol; 2017 Feb; 25(2):79-85. PubMed ID: 28182587
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evolution of Quality Assurance for Clinical Immunohistochemistry in the Era of Precision Medicine: Part 1: Fit-for-Purpose Approach to Classification of Clinical Immunohistochemistry Biomarkers.
    Cheung CC; D'Arrigo C; Dietel M; Francis GD; Gilks CB; Hall JA; Hornick JL; Ibrahim M; Marchetti A; Miller K; van Krieken JH; Nielsen S; Swanson PE; Taylor CR; Vyberg M; Zhou X; Torlakovic EE;
    Appl Immunohistochem Mol Morphol; 2017 Jan; 25(1):4-11. PubMed ID: 27922482
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evolution of Quality Assurance for Clinical Immunohistochemistry in the Era of Precision Medicine: Part 4: Tissue Tools for Quality Assurance in Immunohistochemistry.
    Cheung CC; D'Arrigo C; Dietel M; Francis GD; Fulton R; Gilks CB; Hall JA; Hornick JL; Ibrahim M; Marchetti A; Miller K; van Krieken JH; Nielsen S; Swanson PE; Taylor CR; Vyberg M; Zhou X; Torlakovic EE;
    Appl Immunohistochem Mol Morphol; 2017 Apr; 25(4):227-230. PubMed ID: 27941560
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evolution of Quality Assurance for Clinical Immunohistochemistry in the Era of Precision Medicine. Part 3: Technical Validation of Immunohistochemistry (IHC) Assays in Clinical IHC Laboratories.
    Torlakovic EE; Cheung CC; D'Arrigo C; Dietel M; Francis GD; Gilks CB; Hall JA; Hornick JL; Ibrahim M; Marchetti A; Miller K; van Krieken JH; Nielsen S; Swanson PE; Vyberg M; Zhou X; Taylor CR;
    Appl Immunohistochem Mol Morphol; 2017 Mar; 25(3):151-159. PubMed ID: 28187030
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Monoplex LightCycler polymerase chain reaction quantitation of the HER2 gene for quality assurance of HER2/neu testing by immunohistochemistry and fluorescence in situ hybridization.
    Layfield LJ; Willmore-Payne C; Isom G; Holden JA
    Appl Immunohistochem Mol Morphol; 2008 Dec; 16(6):562-7. PubMed ID: 18948825
    [TBL] [Abstract][Full Text] [Related]  

  • 6. General Guidelines for Quality Assurance of Immunohistochemistry in a Mohs Lab.
    Kinas CG; Carroll BT
    Dermatol Surg; 2017 Apr; 43(4):507-511. PubMed ID: 28359076
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Institutional quality assurance for breast cancer HER2 immunohistochemical testing: identification of outlier results and impact of simultaneous fluorescence in situ hybridization cotesting.
    Green IF; Zynger DL
    Hum Pathol; 2015 Dec; 46(12):1842-9. PubMed ID: 26412217
    [TBL] [Abstract][Full Text] [Related]  

  • 8. EGFR and KRAS quality assurance schemes in pathology: generating normative data for molecular predictive marker analysis in targeted therapy.
    Thunnissen E; Bovée JV; Bruinsma H; van den Brule AJ; Dinjens W; Heideman DA; Meulemans E; Nederlof P; van Noesel C; Prinsen CF; Scheidel K; van de Ven PM; de Weger R; Schuuring E; Ligtenberg M
    J Clin Pathol; 2011 Oct; 64(10):884-92. PubMed ID: 21947301
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunohistochemistry should undergo robust validation equivalent to that of molecular diagnostics.
    Elliott K; McQuaid S; Salto-Tellez M; Maxwell P
    J Clin Pathol; 2015 Oct; 68(10):766-70. PubMed ID: 26280782
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Suggested guidelines for immunohistochemical techniques in veterinary diagnostic laboratories.
    Ramos-Vara JA; Kiupel M; Baszler T; Bliven L; Brodersen B; Chelack B; Czub S; Del Piero F; Dial S; Ehrhart EJ; Graham T; Manning L; Paulsen D; Valli VE; West K;
    J Vet Diagn Invest; 2008 Jul; 20(4):393-413. PubMed ID: 18599844
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fit-for-Purpose Immunohistochemical Biomarkers.
    Torlakovic EE
    Endocr Pathol; 2018 Jun; 29(2):199-205. PubMed ID: 29696583
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Developing ALK Immunohistochemistry and In Situ Hybridization Proficiency Testing for Non-Small Cell Lung Cancer in Canada: Canadian Immunohistochemistry Quality Control Challenges and Successes.
    Cheung CC; Garratt J; Won J; Cutz JC; Gilks BC; Tsao M; Torlakovic EE
    Appl Immunohistochem Mol Morphol; 2015; 23(10):677-81. PubMed ID: 26551338
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Improving Selection Criteria for ALK Inhibitor Therapy in Non-Small Cell Lung Cancer: A Pooled-Data Analysis on Diagnostic Operating Characteristics of Immunohistochemistry.
    Jiang L; Yang H; He P; Liang W; Zhang J; Li J; Liu Y; He J
    Am J Surg Pathol; 2016 May; 40(5):697-703. PubMed ID: 26825369
    [TBL] [Abstract][Full Text] [Related]  

  • 14. ICSH guidelines for the standardization of bone marrow immunohistochemistry.
    Torlakovic EE; Brynes RK; Hyjek E; Lee SH; Kreipe H; Kremer M; McKenna R; Sadahira Y; Tzankov A; Reis M; Porwit A;
    Int J Lab Hematol; 2015 Aug; 37(4):431-49. PubMed ID: 25977137
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Updated UK Recommendations for HER2 assessment in breast cancer.
    Rakha EA; Pinder SE; Bartlett JM; Ibrahim M; Starczynski J; Carder PJ; Provenzano E; Hanby A; Hales S; Lee AH; Ellis IO;
    J Clin Pathol; 2015 Feb; 68(2):93-9. PubMed ID: 25488926
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Academic and nonacademic laboratories perform equally on CIQC immunohistochemistry proficiency testing.
    Chen ZW; Neufeld H; Copete MA; Garratt J; Gilks CB; Torlakovic EE
    Am J Clin Pathol; 2013 Jul; 140(1):55-60. PubMed ID: 23765534
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Call for a European programme in external quality assurance for bone marrow immunohistochemistry; report of a European Bone Marrow Working Group pilot study.
    Torlakovic EE; Naresh K; Kremer M; van der Walt J; Hyjek E; Porwit A
    J Clin Pathol; 2009 Jun; 62(6):547-51. PubMed ID: 19474355
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An Audit of Failed Immunohistochemical Slides in a Clinical Laboratory: The Role of On-Slide Controls.
    Cheung CC; Taylor CR; Torlakovic EE
    Appl Immunohistochem Mol Morphol; 2017; 25(5):308-312. PubMed ID: 26657875
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Validation of Immunohistochemical Assays for Integral Biomarkers in the NCI-MATCH EAY131 Clinical Trial.
    Khoury JD; Wang WL; Prieto VG; Medeiros LJ; Kalhor N; Hameed M; Broaddus R; Hamilton SR
    Clin Cancer Res; 2018 Feb; 24(3):521-531. PubMed ID: 28839110
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Consortium for Analytic Standardization in Immunohistochemistry.
    Bogen SA; Dabbs DJ; Miller KD; Nielsen S; Parry SC; Szabolcs MJ; t'Hart N; Taylor CR; Torlakovic EE
    Arch Pathol Lab Med; 2022 May; 147(5):584-590. PubMed ID: 36084252
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.